Justices block bankruptcy deal that aimed to settle opioid claims with $6 billion settlement
- Supreme Court rejects Purdue Pharma’s bankruptcy plan that would have shielded Sackler family from opioid lawsuits
- Sacklers agreed to pay $6 billion for civil claims related to OxyContin promotion
- Justice Department argued the plan would set a precedent for wealthy corporations to misuse bankruptcy system
The Supreme Court has rejected a bankruptcy plan for OxyContin-maker Purdue Pharma that would have protected the Sackler family from civil lawsuits over their alleged role in fueling the opioid epidemic. The company’s plan, which aimed to allocate billions of dollars to combat addiction, was criticized by the Justice Department for setting a precedent for wealthy corporations to misuse the bankruptcy system. Purdue Pharma and its owners face thousands of lawsuits from individuals and governments over their promotion of OxyContin and its addictive risks.
Factuality Level: 8
Factuality Justification: The article provides accurate and objective information about the Supreme Court’s rejection of Purdue Pharma’s bankruptcy plan and the controversy surrounding the Sackler family’s involvement in the opioid epidemic. It presents both sides of the argument and includes relevant details about the company’s history, legal actions against them, and the settlement offer.
Noise Level: 3
Noise Justification: The article provides relevant information about the Supreme Court’s rejection of Purdue Pharma’s bankruptcy plan and the controversy surrounding the Sackler family’s involvement in the opioid epidemic. It includes details on the settlement offer and the objections from some claimants, as well as the government’s argument against the plan. The article also mentions Purdue’s past legal issues. However, it could have included more analysis or context about the broader implications of this decision for future cases involving wealthy corporations and individuals using bankruptcy to avoid liability.
Public Companies: Purdue Pharma (N/A)
Key People: Sackler family (Family owners of Purdue Pharma), Gregory Garre (Purdue lawyer), Alexander Gladstone (Writer), Jan Wolfe (Writer)
Financial Relevance: Yes
Financial Markets Impacted: The financial markets impacted by this decision include the pharmaceutical industry, specifically opioid-related stocks and related companies.
Financial Rating Justification: This article discusses the bankruptcy plan for OxyContin-maker Purdue Pharma, which has a significant impact on the pharmaceutical industry due to its role in the opioid epidemic. The decision by the Supreme Court affects the Sackler family’s financial settlement and the allocation of funds towards combating opioid addiction. This has implications for other companies involved in similar legal battles and could potentially influence future bankruptcy cases involving wealthy individuals or corporations.
Presence Of Extreme Event: Yes
Nature Of Extreme Event: Legal and Judicial Events
Impact Rating Of The Extreme Event: Severe
Extreme Rating Justification: The extreme event is the rejection of Purdue Pharma’s bankruptcy plan by the Supreme Court, which has significant legal and judicial implications for the Sackler family and their involvement in the opioid epidemic. This decision could have major consequences on future cases involving wealthy corporations attempting to use bankruptcy as a means to avoid civil lawsuits.
www.wsj.com 
